Morphic (MORF)
(Delayed Data from NSDQ)
$55.74 USD
+23.90 (75.06%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $55.80 +0.06 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.74 USD
+23.90 (75.06%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $55.80 +0.06 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
What Makes Morphic (MORF) a New Buy Stock
by Zacks Equity Research
Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stocks to Buy for February 14th
by Zacks Equity Research
LUMN, SFST and MORF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2023.
New Strong Buy Stocks for February 14th
by Zacks Equity Research
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 57.2% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to an 110.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -5.88% and 78.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
by Zacks Equity Research
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
by Zacks Equity Research
The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
by Zacks Equity Research
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
by Zacks Equity Research
Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.